Relationship between epicardial adipose tissue adipocyte size and MCP-1 expression

Eiras, Sonia; Teijeira-Fernández, Elvis; Salgado-Somoza, Antonio; Couso, Elena; García‐Caballero, Tomás; Sierra, Juan; González-Juanatey, José Ramón

doi:10.1016/j.cyto.2010.05.009

Cited by 38 publications

(22 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is likely that adipocyte hypertrophy, a hallmark of inflamed adipose tissue, is critical in the pathogenesis of these metabolic disorders. This is further supported by clinically-relevant findings that adipocyte size positively correlates with MCP-1 expression in humans (Eiras et al, 2010;Skurk et al, 2007). While the role of macrophages in orchestrating adipose tissue inflammation is well established, the role of other innate immune cells in this process is yet to be elucidated.…”

Section: Role Of Innate Immunity In Modulating Adipose Tissue Functionmentioning

confidence: 55%

Immunity as a link between obesity and insulin resistance

Kalupahana

Moustaid‐Moussa

Claycombe

2012

Molecular Aspects of Medicine

218

163

View full text Add to dashboard Cite

Section: Role Of Innate Immunity In Modulating Adipose Tissue Functionmentioning

confidence: 55%

Immunity as a link between obesity and insulin resistance

Kalupahana

Moustaid‐Moussa

Claycombe

2012

Molecular Aspects of Medicine

218

163

View full text Add to dashboard Cite

“…Microscopically, epicardial fat is predominantly composed of adipocytes, but also contains ganglia and interconnecting nerves, inflammatory, stromovascular and immune cells [10]. Epicardial adipocytes are generally smaller than those in subcutaneous and other visceral fat depots, including the pericardial depot [11,12]. The smaller cellular size can be explained by the larger number of pre-adipocytes than mature adipocytes [13].…”

Section: Anatomy Of Epicardial Adipose Tissuementioning

confidence: 99%

Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features

Iacobellis

Bianco

2011

Trends in Endocrinology & Metabolism

454

407

View full text Add to dashboard Cite

Epicardial adipose tissue is an unusual visceral fat depot with anatomical and functional contiguity to the myocardium and coronary arteries. Under physiological conditions, epicardial adipose tissue displays biochemical, mechanical and thermogenic cardioprotective properties. Under pathological circumstances, epicardial fat can locally affect the heart and coronary arteries through vasocrine or paracrine secretion of proinflammatory cytokines. What influences this equilibrium remains unclear. Improved local vascularization, weight loss, and targeted pharmaceutical interventions could help to return epicardial fat to its physiological role. This review focuses on the emerging physiological and pathophysiological aspects of the epicardial fat and its numerous and innovative clinical applications. Particular emphasis is placed on the paracrine/endocrine properties of epicardial fat and its role in the development and progression of atherosclerosis.

show abstract

“…In patients with multiple risk factors for coronary atherosclerosis (CAD), including type 2 diabetes, interleukin (IL)-1β and other proinflammatory genes and proteins are higher in epicardial adipose tissue (EAT) than subcutaneous adipose tissue (SAT) from the same patients (1) or EAT from patients without CAD (2), whereas anti-inflammatory IL-10 is increased (2) and anti-inflammatory adiponectin is reduced (3). The relative expression of pro- and anti-inflammatory mediators may determine whether EAT contributes in a harmful or protective paracrine manner to CAD (4), which might be therapeutically relevant (5).…”

mentioning

confidence: 99%

Inflammatory Genes in Epicardial Fat Contiguous With Coronary Atherosclerosis in the Metabolic Syndrome and Type 2 Diabetes

et al. 2011

View full text Add to dashboard Cite

OBJECTIVETo determine changes in gene expression in epicardial adipose tissue (EAT) associated with coronary atherosclerosis (CAD) and effects of pioglitazone therapy.RESEARCH DESIGN AND METHODSGenes were quantified by RT-PCR in EAT and thoracic subcutaneous adipose tissue (SAT) obtained during surgery in CAD patients with metabolic syndrome (MS) or type 2 diabetes and control subjects with minimal or no CAD and no MS or type 2 diabetes.RESULTSIncreased expression of interleukin-1 receptor antagonist (IL-1Ra) and IL-10, a trend for higher IL-1β, and no change in peroxisome proliferator–activated receptor-γ (PPARγ) was found in EAT from MS or type 2 diabetes. Only PPARγ mRNA was reduced in SAT. Pioglitazone therapy in type 2 diabetes was associated with decreased expression of IL-1β, IL-1Ra, and IL-10 in EAT; decreased IL-10 in SAT; and increased PPARγ in SAT.CONCLUSIONSIn MS and type 2 diabetes with CAD, proinflammatory and anti-inflammatory genes were differentially increased in EAT and selectively reduced in association with pioglitazone treatment.

show abstract

Relationship between epicardial adipose tissue adipocyte size and MCP-1 expression

Cited by 38 publications

References 30 publications

Immunity as a link between obesity and insulin resistance

Immunity as a link between obesity and insulin resistance

Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features

Inflammatory Genes in Epicardial Fat Contiguous With Coronary Atherosclerosis in the Metabolic Syndrome and Type 2 Diabetes

Contact Info

Product

Resources

About